WO2002019996A3 - Prevention of acute sinusitis and sinus attack - Google Patents

Prevention of acute sinusitis and sinus attack Download PDF

Info

Publication number
WO2002019996A3
WO2002019996A3 PCT/IB2001/001522 IB0101522W WO0219996A3 WO 2002019996 A3 WO2002019996 A3 WO 2002019996A3 IB 0101522 W IB0101522 W IB 0101522W WO 0219996 A3 WO0219996 A3 WO 0219996A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
acute sinusitis
sinus
attack
sinus attack
Prior art date
Application number
PCT/IB2001/001522
Other languages
French (fr)
Other versions
WO2002019996A2 (en
Inventor
James T Angello
Howard M Druce
Original Assignee
Warner Lambert Co
James T Angello
Howard M Druce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, James T Angello, Howard M Druce filed Critical Warner Lambert Co
Priority to AU2001279999A priority Critical patent/AU2001279999A1/en
Priority to EP01958276A priority patent/EP1317259A2/en
Priority to BR0113747-6A priority patent/BR0113747A/en
Priority to MXPA03001437A priority patent/MXPA03001437A/en
Priority to JP2002524481A priority patent/JP2004508324A/en
Priority to CA002419653A priority patent/CA2419653A1/en
Publication of WO2002019996A2 publication Critical patent/WO2002019996A2/en
Publication of WO2002019996A3 publication Critical patent/WO2002019996A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Adregnergic alpha agonists such as pseudoephedrine can be used to prevent sinusitus or sinus attack.
PCT/IB2001/001522 2000-09-08 2001-08-23 Prevention of acute sinusitis and sinus attack WO2002019996A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2001279999A AU2001279999A1 (en) 2000-09-08 2001-08-23 Prevention of acute sinusitis and sinus attack
EP01958276A EP1317259A2 (en) 2000-09-08 2001-08-23 Prevention of acute sinusitis and sinus attack
BR0113747-6A BR0113747A (en) 2000-09-08 2001-08-23 Prevention of Acute Sinusitis and Sinus Attack
MXPA03001437A MXPA03001437A (en) 2000-09-08 2001-08-23 Prevention of acute sinusitis and sinus attack.
JP2002524481A JP2004508324A (en) 2000-09-08 2001-08-23 Prevent acute sinusitis and sinus attacks
CA002419653A CA2419653A1 (en) 2000-09-08 2001-08-23 Prevention of acute sinusitis and sinus attack

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65792900A 2000-09-08 2000-09-08
US09/657,929 2000-09-08

Publications (2)

Publication Number Publication Date
WO2002019996A2 WO2002019996A2 (en) 2002-03-14
WO2002019996A3 true WO2002019996A3 (en) 2002-06-13

Family

ID=24639223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001522 WO2002019996A2 (en) 2000-09-08 2001-08-23 Prevention of acute sinusitis and sinus attack

Country Status (7)

Country Link
EP (1) EP1317259A2 (en)
JP (1) JP2004508324A (en)
AU (1) AU2001279999A1 (en)
BR (1) BR0113747A (en)
CA (1) CA2419653A1 (en)
MX (1) MXPA03001437A (en)
WO (1) WO2002019996A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160324890A1 (en) * 2015-05-06 2016-11-10 Robert E. Weinstein Method and Device for Preventing Microbial Resistance

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279976A1 (en) * 1987-01-28 1988-08-31 Alza Corporation Pseudoephedrine dosage form
WO1992017171A1 (en) * 1991-04-01 1992-10-15 Merck & Co., Inc. Ibuprofen-decongestant combinations
US5541210A (en) * 1993-12-17 1996-07-30 The Procter & Gamble Company 5-(2-imidazolinylamino)benzimidazole compounds useful as alpha-2 andrenoceptor agonists
WO1998023596A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
WO1998023612A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists
WO1999015173A1 (en) * 1997-09-19 1999-04-01 The Procter & Gamble Company Compositions and methods for treating respiratory disorders
US5948414A (en) * 1998-03-24 1999-09-07 Nouveau Technologies, Inc. Herbal based nasal spray

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279976A1 (en) * 1987-01-28 1988-08-31 Alza Corporation Pseudoephedrine dosage form
WO1992017171A1 (en) * 1991-04-01 1992-10-15 Merck & Co., Inc. Ibuprofen-decongestant combinations
US5541210A (en) * 1993-12-17 1996-07-30 The Procter & Gamble Company 5-(2-imidazolinylamino)benzimidazole compounds useful as alpha-2 andrenoceptor agonists
WO1998023596A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
WO1998023612A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists
WO1999015173A1 (en) * 1997-09-19 1999-04-01 The Procter & Gamble Company Compositions and methods for treating respiratory disorders
US5948414A (en) * 1998-03-24 1999-09-07 Nouveau Technologies, Inc. Herbal based nasal spray

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FIREMAN P.: "Treatment strategies designed to minimize medical complications of allergic rhinitis.", AMERICAN JOURNAL OF RHINOLOGY, (1997) 11/2 (95-102)., XP002127890 *
MELEN I ET AL: "Effects of Phenylpropanolamine on Ostial and Nasal Patency in Patients Treated for Chronic Maxillary Sinusitis.", ACTA OTOLARYNGOL. (101, NO. 5-6, 494-500, 1986) 2 FIG. 3 TAB. 14 REF. CODEN: AOLAAJ ISSN: 0001-6489, Leo, XP008002013 *

Also Published As

Publication number Publication date
EP1317259A2 (en) 2003-06-11
BR0113747A (en) 2003-06-24
AU2001279999A1 (en) 2002-03-22
JP2004508324A (en) 2004-03-18
WO2002019996A2 (en) 2002-03-14
CA2419653A1 (en) 2002-03-14
MXPA03001437A (en) 2005-06-03

Similar Documents

Publication Publication Date Title
AU2524902A (en) Use of MoO<sub>3</sub> as corrosion inhibitor, and coating composition containing such an inhibitor
AU2001277025A1 (en) Universal transaction manager agent, systems and methods
AU1718400A (en) Method for treating pain
EP1290149A4 (en) Thermostable reverse transcriptases and uses thereof
AU2001247782A1 (en) 18221, dual specificity phosphatase and uses thereof
ZA979236B (en) The preparation and use of ß-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors.
AU2001297724A1 (en) Electronic game enhancement systems and methods
DE69922399D1 (en) FRAGRANTANT COMPOSITIONS CONTAINING CARBOXYLIC ACID AND CYCLOHEXENIC ACID CORROSION INHIBITORS
MXPA03000694A (en) New use of lipase inhibitors.
AU2001241674A1 (en) Variant galactose oxidase, nucleic acid encoding same, and methods of using same
WO2001068146A3 (en) Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
MXPA03002207A (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors.
WO2002001228A8 (en) Interaction of colloid-immobilized species with species on non-colloidal structures
WO2001066144A3 (en) Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
AU2001285914A1 (en) Improved swellable phyllosilicates
WO2002019996A3 (en) Prevention of acute sinusitis and sinus attack
HK1048318A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors.
WO2002022107A3 (en) Pharmaceutical composition having modified carrier
AU2001255594A1 (en) Enzyme variants having one or more d-amino acid substitutions
WO2001053352A3 (en) Sperm specific proteins
AU2002239438A1 (en) 2,4-hexadienoic acid and derivatives as corrosion inhibitors
AU2001252627A1 (en) Polybenzasol fiber and use of the same
HK1060697A1 (en) Novel uses of combined 5-ht1a agonists and serotonin reuptake inhibitors
AU2002218084A1 (en) Inhibitors of thromboxane formation and action
AU2001293557A1 (en) New inhibitors of iapp fibril formation and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001437

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2419653

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001958276

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002524481

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001958276

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001958276

Country of ref document: EP